Development of a novel bioavailable inhibitor of the calmodulin-regulated protein kinase MLCK: A lead compound that attenuates vascular leak

Biochimica et Biophysica Acta - Molecular Cell Research

Volumn 1763, Issue 11, 2006, Pages 1266-1274

  Behanna, Heather A ^a   Watterson, D Martin ^a   Ranaivo, Hantamalala Ralay ^a  

^a NORTHWESTERN UNIVERSITY   (United States)

Author keywords

Barrier dysfunction; Drug discovery; Genetic knockout; Inflammatory disorder; Myosin light chain kinase; Structure activity relationship

Indexed keywords

11 (6 IMINO 3 PHENYLPYRIDAZIN 1(6H) YL) N [2 (1 METHYLPYRROLIDIN 2 YL)ETHYL]UNDECANAMIDE; 3 CHLORO 6 PHENYLPYRIDAZINE; BACTERIAL TOXIN; BACTERIUM LIPOPOLYSACCHARIDE; CYCLIC AMP DEPENDENT PROTEIN KINASE; DEATH ASSOCIATED PROTEIN KINASE; ENDOTOXIN; MYOSIN LIGHT CHAIN KINASE INHIBITOR; N (2 CYCLOPENTYLETHYL) 11 (6 IMINO 3 PHENYLPYRIDAZIN 1(6H) YL)UNDECANAMIDE; N [2 (1H IMIDAZOL 4 YL)ETHYL] 11 (6 IMINO 3 PHENYLPYRIDAZIN 1(6H) YL)UNDECANAMIDE; PROTEIN KINASE C; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; DRUG DESIGN; DRUG METABOLISM; DRUG SCREENING; DRUG STABILITY; DRUG SYNTHESIS; ENDOTHELIAL DYSFUNCTION; ENZYME ACTIVITY; ENZYME INHIBITION; FEMALE; HUMAN; HUMAN CELL; IC 50; KNOCKOUT MOUSE; LIVER MICROSOME; LUNG BLOOD VESSEL; MICROSOME; MOUSE; NONHUMAN; PRIORITY JOURNAL; STRUCTURE ACTIVITY RELATION;

ANIMALS; BIOLOGICAL ASSAY; FEMALE; HUMANS; INHIBITORY CONCENTRATION 50; MICE; MICE, INBRED C57BL; MICROSOMES, LIVER; MYOSIN-LIGHT-CHAIN KINASE; PROTEIN KINASE INHIBITORS; PYRIDAZINES; PYRROLIDINES;

ANIMALIA;

EID: 33751233235     PISSN: 01674889     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.bbamcr.2006.08.007     Document Type: Article

References (49)

1. Dreyfuss D., and Saumon G. Am. J. Respir. Crit. Care Med. 157 (1998) 294-323
2. Graham D.J., Drinkard C.R., and Shatin D. Am. J. Gastroenterol. 98 (2003) 175-179
3. Groeneveld A.B. Vascul. Pharmacol. 39 (2002) 247-256
4. Rubenfeld G.D. Crit. Care Med. 31 (2003) S276-S284
5. Mehta D., and Malik A.B. Physiol. Rev. 86 (2006) 279-367
6. Michel C.C., and Curry F.E. Physiol. Rev. 79 (1999) 703-761
7. Clayburgh D.R., Shen L., and Turner J.R. Lab. Invest. 84 (2004) 282-291
8. Fink M.P., and Delude R.L. Crit. Care Clin. 21 (2005) 177-196
9. Orfanos S.E., Mavrommati I., Korovesi I., and Roussos C. Intensive Care Med. 30 (2004) 1702-1714
10. Plante G.E., Chakir M., Ettaouil K., Lehoux S., and Sirois P. Can. J. Physiol. Pharmacol. 74 (1996) 824-833
11. Demling R.H. J. Burn Care Rehabil. 26 (2005) 207-227
12. Dudek S.M., and Garcia J.G. J. Appl. Physiol. 91 (2001) 1487-1500
13. van Nieuw Amerongen G.P., and van Hinsbergh V.W. Vascul. Pharmacol. 39 (2002) 257-272
14. Yuan S.Y. Vascul. Pharmacol. 39 (2002) 213-223
15. Lukas T.J., Mirzoeva S., and Watterson D.M. In: Van Eldik L.J., and Watterson D.M. (Eds). Calmodulin and Signal Transduction (1998), Academic Press 65-168
16. Verin A.D., Lazar V., Torry R.J., Labarrere C.A., Patterson C.E., and Garcia J.G. Am. J. Respir. Cell Mol. Biol. 19 (1998) 758-766
17. Watterson D.M., Collinge M., Lukas T.J., Van Eldik L.J., Birukov K.G., Stepanova O.V., and Shirinsky V.P. FEBS Lett. 373 (1995) 217-220
18. Wainwright M.S., Rossi J., Schavocky J., Crawford S., Steinhorn D., Velentza A.V., Zasadzki M., Shirinsky V., Jia Y., Haiech J., Van Eldik L.J., and Watterson D.M. Proc. Natl. Acad. Sci. U. S. A. 100 (2003) 6233-6238
19. Clayburgh D.R., Barrett T.A., Tang Y., Meddings J.B., Van Eldik L.J., Watterson D.M., Clarke L.L., Mrsny R.J., and Turner J.R. J. Clin. Invest. 115 (2005) 2702-2715
20. Gluck T., and Opal S.M. Drugs 64 (2004) 837-859
21. Hotchkiss R.S., and Karl I.E. N. Engl. J. Med. 348 (2003) 138-150
22. Bratcher J.M., and Korelitz B.I. Expert Opin. Drug Saf. 5 (2006) 9-16
23. Jacobson J.R., Barnard J.W., Grigoryev D.N., Ma S.F., Tuder R.M., and Garcia J.G. Am. J. Physiol.: Lung Cell Mol. Physiol. 288 (2005) L1026-L1032
24. Merx M.W., and Weber C. Curr. Opin. Crit. Care 12 (2006) 309-314
25. Lukas T.J., Mirzoeva S., Slomczynska U., and Watterson D.M. J. Med. Chem. 42 (1999) 910-919
26. Owens S.E., Graham W.V., Siccardi D., Turner J.R., and Mrsny R.J. Pharm. Res. 22 (2005) 703-709
27. Zolotarevsky Y., Hecht G., Koutsouris A., Gonzalez D.E., Quan C., Tom J., Mrsny R.J., and Turner J.R. Gastroenterology 123 (2002) 163-172
28. Mirzoeva S., Sawkar A., Zasadzki M., Guo L., Velentza A.V., Dunlap V., Bourguignon J.J., Ramstrom H., Haiech J., Van Eldik L.J., and Watterson D.M. J. Med. Chem. 45 (2002) 563-566
29. Velentza A.V., Wainwright M.S., Zasadzki M., Mirzoeva S., Schumacher A.M., Haiech J., Focia P.J., Egli M., and Watterson D.M. Bioorg. Med. Chem. Lett. 13 (2003) 3465-3470
30. Schumacher A.M., Schavocky J.P., Velentza A.V., Mirzoeva S., and Watterson D.M. Biochemistry 43 (2004) 8116-8124
31. Schumacher A.M., Velentza A.V., and Watterson D.M. Expert Opin. Ther. Targets 6 (2002) 497-506
32. Velentza A.V., Schumacher A.M., Weiss C., Egli M., and Watterson D.M. J. Biol. Chem. 276 (2001) 38956-38965
33. Watterson D.M., Mirzoeva S., Guo L., Whyte A., Bourguignon J.J., Hibert M., Haiech J., and Van Eldik L.J. Neurochem. Int. 39 (2001) 459-468
34. Standiford T.J., Kunkel S.L., Lukacs N.W., Greenberger M.J., Danforth J.M., Kunkel R.G., and Strieter R.M. J. Immunol. 155 (1995) 1515-1524
35. Ackley D., Rockich K., and Baker T. In: Caldwell Z.Y.a.G.W. (Ed). Methods in Pharmacology and Toxicology Optimization in Drug Discovery: In Vitro Methods (2004), Humana Press Inc., Totowa, NJ 151-162
36. Watterson D.M., Haiech J., and Van Eldik L.J. J. Mol. Neurosci. 19 (2002) 89-93
37. Watterson D.M., Velentza A.V., Zasadzki M., Craft J.M., Haiech J., and Van Eldik L.J. J. Mol. Neurosci. 20 (2003) 411-423
38. D. Babin, A. Le-Brun, L. Gauzy-Lazo, H. Bouchard (241 pp, Aventis Pharma S.A., Fr., WO 2003).
39. G.W. Bemis, S.L. Harbeson M. Ledeboer (58 pp, USA, US 2004).
40. J. Green, J. Cao, U. Bandarage, H. Gao C. Forster (68 pp, Vertex Pharmaceuticals Incorporated, USA, WO 2006).
41. W. Lee, G. Ladouceur, J. Dumas, R. Smith, S. Ying, G. Wang, Z. Chen, Q. Liu H.H. Mokdad (215 pp, Bayer Pharmaceuticals Corporation, USA, WO 2005).
42. Santagada V., Fiorino F., Perissutti E., Severino B., De Filippis V., Vivenzio B., and Caliendo G. Tetrahedron Lett. 42 (2001) 5171-5173
43. Stahl G.L., Walter R., and Smith C.W. J. Org. Chem. 43 (1978) 2285-2286
44. Cohen O., Feinstein E., and Kimchi A. EMBO J. 16 (1997) 998-1008
45. Vieth M., Siegel M.G., Higgs R.E., Watson I.A., Robertson D.H., Savin K.A., Durst G.L., and Hipskind P.A. J. Med. Chem. 47 (2004) 224-232
46. Huang Q., Xu W., Ustinova E., Wu M., Childs E., Hunter F., and Yuan S. Shock 20 (2003) 363-368
47. Tinsley J.H., Teasdale N.R., and Yuan S.Y. Am. J. Physiol.: Lung Cell Mol. Physiol. 286 (2004) L841-L847
48. Blair S.A., Kane S.V., Clayburgh D.R., and Turner J.R. Lab. Invest. 86 (2006) 191-201
49. Ma T.Y., Boivin M.A., Ye D., Pedram A., and Said H.M. Am. J. Physiol.: Gastrointest. Liver Physiol. 288 (2005) G422-G430